viewValiRx PLC

ValiRx receives new patents in Japan and US for lead compounds

The patents relate to the firm's compounds VAL201 and VAL401, which are currently in clinical trials

ValiRx said the patents extended its geographical reach and endorsed its technology

Cancer-focused biotech ValiRx Plc (LON:VAL) says its technology has been further endorsed with the award of new patents in Japan and the US.

The patents relate to the firm's compounds VAL201 and VAL401, which are currently in Phase I/II and Phase IIB clinical trials to treat prostate and lung cancer respectively.

VAL201 has received a patent in Japan means it now has patent protection in Japan, Europe and Australia and USA, with further patents pending in significant markets across the rest of the world.

Meanwhile, joint venture ValiSeek Limited between ValiRx and Tangent Reprofiling Limited has been told that a third US patent has been granted for VAL401 for treating pancreatic adenocarcinoma.

ValiSeek was formed to progress VAL401 into clinical trials for lung cancer and other cancers.

ValiRx chief executive Dr Satu Vainikka told investors: "The grants of these latest patents further extend the company's global geographic patent coverage and with the VAL201 patent grant also building nicely on our recent early clinical trial success".

In September, the group told investors that lead compound VAL201 was continuing to perform well in the Phase I/II clinical trial it is currently undergoing.

The company confirmed back in June that VAL201 – a potential treatment for prostate cancer – was well tolerated and had shown a high degree of safety.

And recently in Copenhagen, data from the first-in-human (FIH) phase I/II, dose escalation and pharmacokinetic (PK) study to show the safety and tolerability of VAL201 for advanced prostate cancer and other advanced solid tumours, was provided.

The poster presentation showed early indications of efficacy in advanced prostate cancer with no drug-related serious adverse events recorded.

Quick facts: ValiRx PLC

Price: 14.15 GBX

Market: AIM
Market Cap: £7.65 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...



Investor Update: Green light for ValiRx to increase dose of VAL201

Top stories from the Proactive Investors UK newsroom. ValirX (LON:VAL) has received a boost for its prostate cancer treatment VAL201 after UK regulators approved a substantial increase in the doses allowed in future clinical trials. The phase I/II trial so far has met all primary and...

on 20/6/19

2 min read